Xilio Therapeutics, Inc. announced the promotions of Uli Bialucha, Ph.D., to chief scientific officer and Chris Frankenfield to chief legal and administrative officer, each effective as of August 8, 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.085 USD | -5.65% | +0.93% | +98.18% |
05-14 | Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.18% | 42.44M | |
+64.12% | 62.59B | |
-1.86% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.47% | 26.21B | |
-21.88% | 19.09B | |
+3.88% | 13.08B | |
+25.26% | 12.26B | |
+27.94% | 12.05B |
- Stock Market
- Equities
- XLO Stock
- News Xilio Therapeutics, Inc.
- Xilio Therapeutics, Inc. Promotes Uli Bialucha to Chief Scientific Officer and Chris Frankenfield to Chief Legal and Administrative Officer